1. Agarwal E, Chaudhuri A, Leiphrakpam PD, Haferbier KL, Brat-tain MG, Chowdhury S. Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer. BMC Cancer 2014; 14: 145.
2.
Alizadeh A, Dyck SM, Karimi-Abdolrezaee S. Traumatic spinal cord injury: An overview of pathophysiology, models and acute injury mechanisms. Front Neurol 2019; 10: 282.
3.
Anjum A, Yazid MD, Fauzi Daud M, Idris J, Ng AMH, Selvi Naicker A, Ismail OHR, Athi Kumar RK, Lokanathan Y. Spinal cord injury: Pathophysiology, multimolecular interactions, and underlying recovery mechanisms. Int J Mol Sci 2020; 21: 7533.
4.
Ata Yaseen Abdulqader Y, Abdel Kawy HS, Mohammed Alkreathy H, Abdullah Rajeh N. The potential antiepileptic activity of astaxanthin in epileptic rats treated with valproic acid. Saudi Pharm J 2021; 29: 418-426.
5.
Beyer WF, Fridovich I. Assaying for superoxide dismutase activity, some large consequences of minor changes in conditions. Anal Biochem 1987; 161: 559-566.
6.
Bhattacharyya A, Chattopadhyay R, Mitra S, Crowe SE. Oxidative stress: an essential factor in the pathogenesis of gastrointestinal mucosal diseases. Physiol Rev 2014; 94: 329-354.
7.
Chen M, Yu Y, Mi T, Guo Q, Xiang B, Tian X, Jin L, Long C, Shen L, Liu X, Pan J, Zhang Y, Xu T, Zhang D, Wei G. MK-2206 alleviates renal fibrosis by suppressing the Akt/mTOR signaling pathway in vivo and in vitro. Cells 2022; 11: 3505.
8.
Chen X, Cui D, Bi Y, Shu J, Xiong X, Zhao Y. AKT inhibitor MK-2206 sensitizes breast cancer cells to MLN4924, a first-in-class NEDD8-activating enzyme (NAE) inhibitor. Cell Cycle 2018; 17: 2069-2079.
9.
Cheng Y, Zhang Y, Zhang L, Ren X, Huber-Keener KJ, Liu X, Zhou L, Liao J, Keihack H, Yan L, Rubin E, Yang JM. MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Mol Cancer Ther 2012; 11: 154-164.
10.
Cui H, Cheng Y, He Y, Cheng W, Zhao W, Zhao H, Zhou FH, Wang L, Dong J, Cai S. The AKT inhibitor MK2206 suppresses airway inflammation and the pro-remodeling pathway in a TDI‑induced asthma mouse model. Mol Med Rep 2020; 22: 3723-3734.
11.
Harikrishnan VS, Palekkodan H, Fasaludeen A, Krishnan LK, Abelson KSP. Refinement of the spinal cord injury rat model and validation of its applicability as a model for memory loss and chronic pain. Heliyon 2021; 7: e07500.
12.
Hassan B, Akcakanat A, Holder AM, Meric-Bernstam F. Targeting the PI3-kinase/Akt/mTOR signaling pathway. Surg Oncol Clin N Am 2013; 22: 641-664.
13.
He X, Li Y, Deng B, Lin A, Zhang G, Ma M, Wang Y, Yang Y, Kang X. The PI3K/AKT signalling pathway in inflammation, cell death and glial scar formation after traumatic spinal cord injury: Mechanisms and therapeutic opportunities. Cell Prolif 2022; 55: e13275.
14.
Heath RL, Packer L. Photoperoxidation in isolated chloroplasts. I. Stoichiometry of fatty acid peroxidation. Arch Biochem Biophys 1968; 125: 189-198.
15.
Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, Kotani H. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010; 9: 1956-1967.
16.
Kim HY, Lee HJ, Kim TL, Kim E, Ham D, Lee J, Kim T, Shin JW, Son M, Sung JH, Han ZA. Prevalence and characteristics of neuropathic pain in patients with spinal cord injury referred to a rehabilitation center. Ann Rehabil Med 2020; 44: 438-449.
17.
Li Q, Kang C. Mechanisms of action for small molecules revealed by structural biology in drug discovery. Int J Mol Sci 2020; 21: 5262.
18.
Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z, Li W, Hu J, Lu C, Liu Y. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis 2020; 11: 797.
19.
Muller WA. Getting leukocytes to the site of inflammation. Vet Pathol 2013; 50: 7-22.
20.
Paglia DE, Valentine WN. Studies on the quantitative andqualitative characterisation of erythrocyte glutathione peroxidase. J Lab Clin Med 1967; 70: 158-169.
21.
Poljsak B. Strategies for reducing or preventing the generation of oxidative stress. Oxid Med Cell Longev 2011; 2011: 194586.
22.
Ren Y, Young W. Managing inflammation after spinal cord injury through manipulation of macrophage function. Neural Plast 2013; 2013: 945034.
23.
Sezer N, Akkuş S, Uğurlu FG. Chronic complications of spinal cord injury. World J Orthop 2015; 6: 24-33.
24.
Shi Z, Yuan S, Shi L, Li J, Ning G, Kong X, Feng S. Programmed cell death in spinal cord injury pathogenesis and therapy. Cell Prolif 2021; 54: e12992.
25.
Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol 2019; 20: 175-193.
26.
Tan Y, Uchida K, Nakajima H, Guerrero AR, Watanabe S, Hirai T, Takeura N, Liu SY, Johnson WE, Baba H. Blockade of interleukin 6 signaling improves the survival rate of transplanted bone marrow stromal cells and increases locomotor function in mice with spinal cord injury. J Neuropathol Exp Neurol 2013; 72: 980-993.
27.
Tao K, Yin Y, Shen Q, Chen Y, Li R, Chang W, Bai J, Liu W, Shi L, Zhang P. Akt inhibitor MK-2206 enhances the effect of cisplatin in gastric cancer cells. Biomed Rep 2016; 4: 365-368.
